Nkgen Biotech, INC

NKGen Biotech, Inc. has amended its equity and business loan agreement with BDW Investments, LLC, modifying security interests and lien provisions.

NKGen Biotech entered into a third amendment to its secured convertible loan agreement, securing $2.42 million in additional funding.

NKGen Biotech entered into a second amendment to its secured convertible loan agreement, securing $412,500 in additional funding.

NKGen Biotech, Inc. has amended its secured convertible loan agreement, securing an additional $607,200 loan and issuing a new warrant, alongside a voting agreement to increase authorized shares.

NKGen Biotech has entered into a $39.9 million secured convertible loan agreement to refinance existing debt and provide additional working capital.

NKGen Biotech, Inc. amended its secured promissory note with AlpineBrook Capital GP I Limited, securing an additional $343,000 in funding, increasing the total principal to $27,101,106.

NKGen Biotech reported a net income of $15.35 million for Q1 2025, primarily driven by non-cash gains, while facing significant liquidity challenges, debt defaults, and a delisting from Nasdaq.

NKGen Biotech's Q3 2024 results reveal a complex financial landscape marked by a net income of $6.6 million alongside ongoing efforts to secure additional funding and address going concern uncertainties.

NKGen Biotech's second quarter 2024 results reveal ongoing losses and significant financial activity, including debt and equity transactions, as the company navigates its clinical development and public company status.

NKGen Biotech's first quarter 2024 results reveal ongoing losses and significant financial activity, including debt issuances and amendments to forward purchase agreements.

NKGen Biotech filed an amendment to its annual report on Form 10-K to include previously omitted information regarding directors, executive officers, and corporate governance, as well as certain exhibits.

NKGen Biotech, Inc. has released its Code of Business Conduct and Ethics and filed its 10-K annual report, outlining its commitment to ethical practices and providing a detailed overview of its financial performance and business activities.

CFIC-2015 NV Family Investments, LLC, a 10% owner and entity controlled by directors Andrew and Peggy Cherng, has acquired over 19.6 million shares and received warrants for an additional 39.3 million shares of NKGen Biotech, Inc. common stock.

NKGen Biotech's CEO, Paul Y. Song, recently acquired shares and warrants of the company's common stock.

Graf Acquisition Partners IV LLC distributed shares and warrants of NKGen Biotech to its members following the one-year anniversary of the business combination.

Graf Acquisition Partners IV LLC, a significant shareholder of NKGen Biotech, Inc., reported the distribution of common stock, private placement warrants, and working capital warrants to its members.

Kathleen D. Scott, a director at NKGen Biotech, was granted stock options for 800,000 shares on December 6, 2024, under the company's 2023 Equity Incentive Plan.

NKGen Biotech granted Michael Klowden a total of 800,000 stock options on December 6, 2024, under the company's 2023 Equity Incentive Plan.

NKGen Biotech is seeking stockholder approval for a reverse stock split to regain compliance with Nasdaq's minimum bid price requirement and potentially improve stock marketability.

NKGen Biotech is holding its annual meeting on August 28, 2024, to vote on the election of a director, the potential issuance of shares exceeding 19.99% of outstanding shares, and authorization to adjourn the meeting if necessary.

NKGen Biotech has filed an amendment to its S-1 registration statement, outlining plans for the potential issuance of common stock upon exercise of warrants and conversion of notes, as well as the resale of common stock by existing securityholders.

NKGen Biotech aims to raise capital through the potential exercise of outstanding warrants while registering the resale of a significant number of common shares by existing securityholders.

CFIC-2015 NV Family Investments, LLC and its principals, Andrew and Peggy Cherng, have significantly increased their beneficial ownership in NKGen Biotech, Inc. to 47.2% through a recent $2.5 million private placement and associated warrants, signaling a strong investment interest and intent to monitor corporate governance.

NKGen Biotech, Inc. CEO Paul Y. Song has significantly increased his beneficial ownership to 54.3% of the company's common stock through a $2.65 million private placement, acquiring shares and warrants.

Meteora Capital, LLC and its managing member Vik Mittal have disclosed a 6.13% beneficial ownership stake in NKGen Biotech, Inc., held in the ordinary course of business.

Pathstone Family Office, LLC has filed a Schedule 13G, reporting beneficial ownership of 7.91% of NKGen Biotech, Inc.'s common stock as of October 17, 2024.

Meteora Capital, LLC and its Managing Member Vik Mittal have disclosed a beneficial ownership of 7.84% in NKGen Biotech, Inc.'s common stock as of December 31, 2024.